Table 5 Adverse events leading to discontinuations of T2D study medication at 1-year ± 2-months of treatment (Full Analysis Set)
AE leading to discontinuation, n (%) | Empagliflozin (N = 1697) | GLP-1 RA (N = 332) | Other SGLT2i (N = 536) | Total (N = 3618) |
|---|---|---|---|---|
Total AEs | 32 (1.89) | 3 (0.90) | 8 (1.49) | 43 (1.19) |
Gastrointestinal AEs | ||||
Nausea | 1 (0.06) | 2 (0.60) | 3 (0.08) | |
Dyspepsia | 2 (0.12) | 2 (0.06) | ||
Vomiting | 2 (0.12) | 2 (0.06) | ||
Abdominal pain | 3 (0.18) | 3 (0.08) | ||
Other | 1 (0.30) | 1 (0.03) | ||
Genitourinary infections | ||||
Vaginal moniliasis | 1 (0.19) | 1 (0.03) | ||
Vulvovaginitis | 4 (0.24) | 1 (0.19) | 5 (0.14) | |
Balanitis and other genital infections | 6 (0.35) | 1 (0.19) | 7 (0.19) | |
Urinary tract infection (including pyelonephritis and urosepsis) | 4 (0.24) | 1 (0.19) | 5 (0.14) | |
Renal AEs | ||||
Glomerular filtration rate decreased | 1 (0.06) | 1 (0.03) | ||
Urinary AEs | ||||
Increased urination | 3 (0.18) | 1 (0.19) | 4 (0.11) | |
Dysuria | 9 (0.53) | 2 (0.37) | 11 (0.30) | |
Other | 1 (0.06) | 1 (0.19) | 2 (0.06) | |
Metabolic AEs | ||||
Thirst | 1 (0.06) | 1 (0.03) | ||
Cardiovascular AEs | ||||
Cerebrovascular event | 1 (0.06) | 1 (0.03) | ||